Drugs / HS-10506
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07535970 | Apr → Jul 2026 overdue | — | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05953506 | Jul → Dec 2023 | — | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06279286 | May 2024 → Jan 2025 | insomnia | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07677384 | Jun 2026 → Jun 2029 expected | insomnia | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07587385 | May 2026 → Jun 2028 expected | insomnia | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-04-21 | Hansoh BioMedical R&D Company | Results AAN 2026 | 翰森制药OX2R拮抗剂HS-10506用于失眠患者治疗的Ⅰb/Ⅱ期研究数据发布 hansoh.cn ↗
HS-10506在改善睡眠启动和维持方面表现出显著的疗效，同时具有良好的安全性和药代动力学特征. |
| 2026-04-17 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results AAN 2026 | HANSOH PHARMA PRESENTED PHASE 1B/2 DATA OF HS-10506 (A SELECTIVE OREXIN-2 RECEPTOR ANTAGONIST) IN INSOMNIA hspharm.com ↗
HS-10506 has shown significant efficacy in improving sleep onset and maintenance, along with favorable safety and pharmacokinetics profiles. |
| 2024-09-25 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results ECNP 2024| HANSOH PHARMA RELEASED THE LATEST CLINICAL STUDY DATA OF HS-10506 hspharm.com ↗
The recently published clinical trial results of HS-10506 was safe and well-tolerated following a single oral dose up to 60 mg with a favorable PK profile and a desired pharmacodynamic (somnolence) effect. |
| 2024-09-23 | Hansoh BioMedical R&D Company | Results ECNP 2024 | 翰森制药HS-10506最新研究成果发布 hansoh.cn ↗ |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-21 | Hansoh BioMedical R&D Company | AAN 2026 | 翰森制药OX2R拮抗剂HS-10506用于失眠患者治疗的Ⅰb/Ⅱ期研究数据发布 hansoh.cn ↗ |
| 2026-04-17 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | AAN 2026 | HANSOH PHARMA PRESENTED PHASE 1B/2 DATA OF HS-10506 (A SELECTIVE OREXIN-2 RECEPTOR ANTAGONIST) IN INSOMNIA hspharm.com ↗ |
| 2024-09-25 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | ECNP 2024| HANSOH PHARMA RELEASED THE LATEST CLINICAL STUDY DATA OF HS-10506 hspharm.com ↗ |
| 2024-09-23 | Hansoh BioMedical R&D Company | ECNP 2024 | 翰森制药HS-10506最新研究成果发布 hansoh.cn ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10506 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05953506 ↗ |
| Route | Oral | “administered orally” NCT05953506 ↗ |